ArticleViruses2021
Application of Environment-Friendly Rhamnolipids against Transmission of Enveloped Viruses Like SARS-CoV2.
Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 26 citations in OpenAlex.
- Beyond antibiotics: the expanding horizon of microbial natural products.Frontiers in antibiotics · 2026Review
- Article
- Sugar Esters of Fatty Acids: Chemo-Enzymatic Synthesis and Biological Activity.Molecules (Basel, Switzerland) · 2025Review
- A Comprehensive Review on Bioactive Molecules and Advanced Microorganism Management Technologies.Current issues in molecular biology · 2024Review
- Biosurfactants in the sustainable eradication of SARS COV-2 from the environmental surfaces.3 Biotech · 2022Review
- Rhamnolipid Micellization and Adsorption Properties.International journal of molecular sciences · 2022Article
- Variations in Cell Surface ACE2 Levels Alter Direct Binding of SARS-CoV-2 Spike Protein and Viral Infectivity: Implications for Measuring Spike Protein Interactions with Animal ACE2 Orthologs.Journal of virology · 2022Article
- Antimicrobial Compounds from Microorganisms.Antibiotics (Basel, Switzerland) · 2022Review
- Antiviral Activity of the Rhamnolipids Mixture from the Antarctic BacteriumPharmaceutics · 2021Article
- Sophorolipid: a glycolipid biosurfactant as a potential therapeutic agent against COVID-19.Bioengineered · 2021Review
- Variations in cell-surface ACE2 levels alter direct binding of SARS-CoV-2 Spike protein and viral infectivity: Implications for measuring Spike protein interactions with animal ACE2 orthologs.bioRxiv : the preprint server for biology · 2021Article
- Recent Advances in Biomedical, Therapeutic and Pharmaceutical Applications of Microbial Surfactants.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the face of new emerging respiratory viruses, such as SARS-CoV2, vaccines and drug therapies are not immediately available to curb the spread of infection. Non-pharmaceutical interventions, such as mask-wearing and social distance, can slow the transmission. However, both mask and social distance have not prevented the spread of respiratory viruses SARS-CoV2 within the US. There is an urgent need to develop an intervention that could reduce the spread of respiratory viruses. The key to preventing transmission is to eliminate the emission of SARS-CoV2 from an infected person and stop the virus from propagating in the human population. Rhamnolipids are environmentally friendly surfactants that are less toxic than the synthetic surfactants. In this study, rhamnolipid products, 222B, were investigated as disinfectants against enveloped viruses, such as bovine coronavirus and herpes simplex virus 1 (HSV-1). The 222B at 0.009% and 0.0045% completely inactivated 6 and 4 log PFU/mL of HSV-1 in 5-10 min, respectively. 222B at or below 0.005% is also biologically safe. Moreover, 50 μL of 222B at 0.005% on ~1 cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.